pI: 9.0922 |
Length (AA): 516 |
MW (Da): 58243 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_154588)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.25.2430 | casein kinase I, putative |
Leishmania donovani | LdBPK_251640.1 | casein kinase I, putative |
Leishmania infantum | LinJ.25.1640 | casein kinase I, putative |
Leishmania major | LmjF.25.1580 | casein kinase I, putative |
Leishmania mexicana | LmxM.25.1580 | casein kinase I, putative |
Trypanosoma brucei gambiense | Tbg972.3.1460 | casein kinase 1, putative |
Trypanosoma brucei | Tb927.3.1630 | casein kinase 1, putative |
Trypanosoma congolense | TcIL3000_3_730 | casein kinase 1, putative |
Trypanosoma cruzi | TcCLB.510089.170 | casein kinase I, putative |
Trypanosoma cruzi | TcCLB.510421.180 | casein kinase I, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.3.1630 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.3.1630 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.3.1630 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.3.1630 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Rattus norvegicus | Casein kinase I delta | 415 aa | 44.6% | 334 aa | Compounds | References |
Rattus norvegicus | Serine/threonine-protein kinase pim-3 | 326 aa | 22.6% | 318 aa | Compounds | References |
Sus scrofa | Casein kinase 1, delta tv1 | 415 aa | 44.6% | 334 aa | Compounds | References |
Bos taurus | Casein kinase I isoform alpha | 325 aa | 44.2% | 328 aa | Compounds | References |